Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Main billing specialty: gastroenterology.
Medicare fee-for-service ERCP & endoscopic ultrasound cases in the 49 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 165 | 12,633+0.7%/yr | +0.7%/yr | 3.91.1× | 1% | 15,600 in 2030+3.6%/yr |
| Florida | 119 | 8,114−0.6%/yr | −0.6%/yr | 3.71.0× | 6% | 9,910 in 2030+3.4%/yr |
| Texas | 130 | 7,585−0.2%/yr | −0.2%/yr | 3.61.0× | 6% | 10,200 in 2030+5.1%/yr |
| New York | 101 | 6,049−4.1%/yr | −4.1%/yr | 3.41.0× | 1% | 6,420 in 2030+1%/yr |
| Pennsylvania | 86 | 5,501−2.6%/yr | −2.6%/yr | 4.11.2× | 1% | 6,190 in 2030+2%/yr |
| Illinois | 80 | 5,038−0.4%/yr | −0.4%/yr | 3.71.0× | 1% | 6,770 in 2030+5.1%/yr |
| Massachusetts | 60 | 4,610+2.9%/yr | +2.9%/yr | 4.91.4× | 0% | 6,530 in 2030+6%/yr |
| Missouri | 46 | 4,278−2.6%/yr | −2.6%/yr | 7.12.0× | 2% | 4,480 in 2030+0.8%/yr |
| North Carolina | 52 | 3,646−1.8%/yr | −1.8%/yr | 3.81.1× | 5% | 3,960 in 2030+1.4%/yr |
| Ohio | 60 | 3,607−1.1%/yr | −1.1%/yr | 3.30.9× | 1% | 4,620 in 2030+4.2%/yr |
| Michigan | 53 | 3,574+1.2%/yr | +1.2%/yr | 4.31.2× | 1% | 4,510 in 2030+4%/yr |
| Virginia | 48 | 3,175+1.2%/yr | +1.2%/yr | 3.10.9× | 0% | 3,690 in 2030+2.6%/yr |
| New Jersey | 46 | 3,131−1%/yr | −1%/yr | 3.00.9× | 3% | 3,440 in 2030+1.6%/yr |
| Washington | 46 | 2,920−2.5%/yr | −2.5%/yr | 3.91.1× | 0% | 3,710 in 2030+4.1%/yr |
| Arizona | 36 | 2,770+2.8%/yr | +2.8%/yr | 3.81.1× | 2% | 3,300 in 2030+3%/yr |
| Indiana | 42 | 2,562−1%/yr | −1%/yr | 3.71.0× | 3% | 3,260 in 2030+4.1%/yr |
| Maryland | 36 | 2,499+2.9%/yr | +2.9%/yr | 2.90.8× | 1% | 3,770 in 2030+7.1%/yr |
| Minnesota | 37 | 2,446−5.1%/yr | −5.1%/yr | 5.51.6× | 3% | 3,110 in 2030+4.1%/yr |
| South Carolina | 38 | 2,414+3.9%/yr | +3.9%/yr | 3.61.0× | 1% | 3,510 in 2030+6.4%/yr |
| Tennessee | 45 | 1,981−2.7%/yr | −2.7%/yr | 2.90.8× | 7% | 2,310 in 2030+2.6%/yr |
| Georgia | 39 | 1,940−4.2%/yr | −4.2%/yr | 2.30.6× | 0% | 2,330 in 2030+3.1%/yr |
| Colorado | 25 | 1,932+0.7%/yr | +0.7%/yr | 4.11.1× | 0% | 2,030 in 2030+0.9%/yr |
| Wisconsin | 40 | 1,723−4.1%/yr | −4.1%/yr | 3.10.9× | 0% | 1,930 in 2030+1.9%/yr |
| Kentucky | 24 | 1,609−3%/yr | −3%/yr | 3.61.0× | 2% | 1,660 in 2030+0.5%/yr |
| Louisiana | 24 | 1,549−3.9%/yr | −3.9%/yr | 3.91.1× | 11% | 1,580 in 2030+0.3%/yr |
| Alabama | 21 | 1,343−4.1%/yr | −4.1%/yr | 3.10.9× | 11% | 1,700 in 2030+4%/yr |
| Connecticut | 21 | 1,255−2.8%/yr | −2.8%/yr | 3.91.1× | 0% | 1,450 in 2030+2.4%/yr |
| Oregon | 26 | 1,050−5.1%/yr | −5.1%/yr | 2.60.7× | 0% | 1,370 in 2030+4.6%/yr |
| Nebraska | 11 | 985−1.3%/yr | −1.3%/yr | 3.81.1× | 3% | 1,130 in 2030+2.4%/yr |
| West Virginia | 12 | 913−4.3%/yr | −4.3%/yr | 4.51.3× | 0% | 1,000 in 2030+1.5%/yr |
| Oklahoma | 13 | 913−5.4%/yr | −5.4%/yr | 1.90.5× | 0% | 1,080 in 2030+2.9%/yr |
| Kansas | 10 | 846−4%/yr | −4%/yr | 2.10.6× | 2% | 840 in 2030−0.2%/yr |
| Iowa | 11 | 822−0.4%/yr | −0.4%/yr | 1.90.5× | 1% | 920 in 2030+2%/yr |
| Arkansas | 12 | 721−1.7%/yr | −1.7%/yr | 1.90.5× | 0% | 990 in 2030+5.4%/yr |
| District of Columbia | 6 | 706−0.3%/yr | −0.3%/yr | 11.43.2× | 0% | 760 in 2030+1.2%/yr |
| New Hampshire | 10 | 688+1.5%/yr | +1.5%/yr | 3.10.9× | 0% | 920 in 2030+5%/yr |
| Nevada | 10 | 659−2.7%/yr | −2.7%/yr | 2.30.7× | 0% | 610 in 2030−1.4%/yr |
| Mississippi | 11 | 634−4%/yr | −4%/yr | 1.70.5× | 5% | 710 in 2030+1.9%/yr |
| Idaho | 12 | 559+4.8%/yr | +4.8%/yr | 2.80.8× | 0% | 1,080 in 2030+12%/yr |
| North Dakota | 7 | 463+12%/yr | +12%/yr | 4.71.3× | 0% | 800 in 2030+9.4%/yr |
| Utah | 12 | 445−6.8%/yr | −6.8%/yr | 2.10.6× | 0% | 480 in 2030+1.3%/yr |
| Delaware | 10 | 417−1.5%/yr | −1.5%/yr | 2.50.7× | 0% | 470 in 2030+2%/yr |
| Maine | 6 | 387−3.6%/yr | −3.6%/yr | 2.50.7× | 0% | 440 in 2030+2.2%/yr |
| Montana | 8 | 373−4.1%/yr | −4.1%/yr | 2.00.6× | 0% | 440 in 2030+2.8%/yr |
| New Mexico | 8 | 365−15%/yr | −15%/yr | 1.60.5× | 0% | 390 in 2030+1.1%/yr |
| South Dakota | 5 | 279−1.6%/yr | −1.6%/yr | 2.20.6× | 0% | 390 in 2030+5.9%/yr |
| Rhode Island | 5 | 246−4.6%/yr | −4.6%/yr | 2.80.8× | 0% | 240 in 2030−0.5%/yr |
| Alaska | 4 | 213+6.2%/yr | +6.2%/yr | 1.80.5× | 0% | 220 in 2030+0.8%/yr |
| Hawaii | 5 | 193−5.6%/yr | −5.6%/yr | 1.50.4× | 1% | 340 in 2030+10%/yr |
Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 23 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 8 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Olympus | 6 |
| Fujifilm | 5 |
| Pentax Of America | 5 |
| Pentax Medical | 3 |
| Ambu | 1 |
| Ambu Innovation | 1 |
| Boston Scientific | 1 |
| Fujifilm Medical Systems | 1 |
Product codes: FDT (duodenoscope and accessories, flexible/rigid). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 24% of the cases CMS names in California; 68 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 17,732 | 3,622,736−2.9%/yr | −2.9%/yr | 3,877,600 in 2030+1.1%/yr |
| Bronchoscopy & lung nodule | 1,570 | 101,765+4.5%/yr | +4.5%/yr | 172,300 in 2030+9.2%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 25 companies reported engagement with surgeons in the covered states worth $5.7M in consulting, speaking, meals and travel tied to these products, about $3,293 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.